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Abstract 
A 41-year-old Japanese man had received successful interferon (IFN) therapy against 
chronic hepatitis C in 1994. Since then, serum hepatitis C virus (HCV) RNA had been 
negative, and aminotransferase levels had been continuously normal. He had abstained 
from alcohol. However, his serum aminotransferase levels showed slight elevation as his 
body weight increased gradually. He was diagnosed as having fatty liver and diabetes 
mellitus. In January 2006, 11 and a half years after the resolution of HCV infection, he was 
found to have a hepatic nodule 4.0 cm in diameter at liver S4/8 region by plain 
abdominal CT at an annual follow-up examination. He was diagnosed as having 
hepatocellular carcinoma (HCC) by angiography. The tumor was curatively resected and 
its histological diagnosis was moderately differentiated HCC. Noncancerous lesion of the 
liver revealed fibrosis of stage F2 and mild inflammation of grade A1 with mild steatosis. 
This case suggests that all patients with chronic HCV infection should be followed as 
long as possible for the potential development of HCC even after clearance of the virus. 
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Introduction 
The incidence of hepatocellular carcinoma (HCC) is increasing in the United States, 
Europe, and worldwide, and has become a serious problem in many countries [1, 2]. 
Patients with chronic liver disease related to hepatitis B or C virus infection are at high 
risk for developing HCC [3], and the risk of HCC development becomes higher as fibrosis 
of the liver advances. Indeed, it is reported that the risk of HCC development in cirrhotic 
patients with hepatitis C virus (HCV) infection is as high as 7% per year in Japan [4]. 
Interferon (IFN) has a potent antiviral effect and has been widely used for the treatment 
of chronic HCV infection [5]. IFN therapy improves inflammation and fibrosis in the 
liver of the patients and reduces the risk of HCC development, particularly when it results 
in sustained virological response [6–8]. On the other hand, there are several reports that 
describe HCC development long after the clearance of HCV by successful IFN therapy 
[9–11]. Therefore, it is still uncertain how long the patients hold the risk of HCC 
development after the resolution of chronic HCV infection. In the current report, we 
describe a patient who developed HCC 11 and a half years after the clearance of HCV. 
Case Report 
A 41-year-old Japanese man was found to be seropositive for anti-HCV antibody (Dainabot, Tokyo, 
Japan) with abnormal liver function tests at a health check-up in 1994. He had no history of blood 
transfusion or drug abuse, but had been consuming approximately 25 g/day of alcohol for 20 years. He 
was introduced to Nagoya University Hospital (Nagoya, Japan). Serum HCV RNA detected by reverse 
transcription and nested PCR was positive. Serum hepatitis B surface antigen (HBsAg) and antibody to 
HBsAg (anti-HBs) were negative. A liver biopsy specimen was consistent with the feature of chronic 
hepatitis showing moderate fibrosis and mild necroinflammatory reaction, diagnosed later as F2/A1 
according to the classification by Desmet et al. [12]. He was diagnosed to have chronic hepatitis C 
(CH-C) and received IFN monotherapy with natural IFN alpha (human lymphoblastoid IFN; 
Sumitomo Pharmaceutical Co., Osaka, Japan), 6 million units (MU), every day for the first 2 weeks and 
three times a week for the following 22 weeks. HCV RNA became negative during therapy, and the 
negativity of HCV RNA continued during 6 months of follow-up after discontinuation of therapy. 
Serum levels of aminotransaminases were also normal during the same period. He was judged to have 
achieved sustained virological response in HCV treatment. 
He abstained from alcohol during and after the IFN therapy, but his body weight showed a gradual 
increase with slight elevation of serum aminotransferase levels. He was diagnosed to have fatty liver and 
diabetes mellitus, but treatment was not introduced. In January 2006, he was found to have a hepatic 
nodule 4.0 cm in diameter at liver S4/8 region by plain abdominal CT at an annual follow-up 
examination. 
He was admitted to our hospital (Department of Gastroenterology, Aichi Medical University 
Hospital, Aichi, Japan) in February 2006. On admission, his height was 162 cm and his body weight 
72 kg. Physical examination was unremarkable; the liver and spleen were not palpable, and jaundice, 
ascites, peripheral edema and other signs of chronic liver disease were not observed. Complete blood 
counts (CBC) were normal (white blood cell count 6,900/μl, hemoglobin 14.4 g/dl, and platelet count 
253,000/μl). Liver function tests were normal; serum levels of transaminases and total bilirubin were 
within normal range (AST 22 IU/l, ALT 23 IU/l, and total bilirubin 0.9 mg/dl). Other laboratory tests, 
including liver fibrosis markers such as type IV collagen 7s, type III procollagen-N-peptide and 
hyaluronic acid, were also within normal range. However, fasting blood sugar (128 mg/dl) and HbA1c 
(6.8%) were slightly elevated (table 1). Serum tumor makers of HCC were within normal range, 
prothrombin induced by vitamin K absence-II (PIVKA-II) level was 18 mAU/ml (normal range 
<40 mAU/ml), and α-fetoprotein level was 4.4 ng/ml (normal range <10 ng/ml). He was seropositive for 
anti-HCV by a second-generation enzyme immunoassay (Dainabot, Tokyo, Japan) and seronegative for 
HCV RNA by Amplicore HCV test (Roche Diagnostic Inc., Tokyo, Japan). 
On dynamic CT, the nodule on liver S8 area revealed a tumor staining of 4.0 cm in diameter in the 
early arterial phase and modest washout density in the post-vascular phase (fig. 1a, b). On 
contrast-enhanced US scan, blood inflow into the same nodule was detected in the early arterial phase,  
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and the nodule became hypoechoic compared to the liver parenchyma in the post-vascular phase. Celiac 
angiography revealed a hypervascular tumor with proliferation of fine tumor vessels (which also showed 
nodular and mosaic features) at the S4/8 region of the liver, just below the dome of right the diaphragm 
(fig. 2). The findings were compatible with HCC. 
Percutaneous liver biopsy was performed at the noncancerous lesion, and the specimen showed 
fibrosis of stage F2 and mild inflammation of grade A1 with mild steatosis (fig. 3a, b). The tumor was 
curatively resected without any complication, and the histological study of the resected specimen 
revealed that the tumor was a moderately differentiated HCC (fig. 4). 
Discussion 
In the present study we describe a patient with HCC who developed HCC 11 and a half 
years after the eradication of HCV. There are many reports aimed to elucidate the risk 
factors for liver carcinogenesis, and some of them have tried to examine the incidence of 
HCC in patients with CH-C after IFN therapy [6–8]. Kasahara et al. examined the risk of 
HCC development in CH-C patients treated by IFN and showed that the cumulative 
incidence of HCC in relapsers (transient responders) to IFN therapy was almost equal to 
that in sustained responders, and that it was significantly higher in nonresponders than in 
sustained and transient responders [6]. The seventh-year cumulative incidence rates of 
HCC in sustained responders, relapsers, and nonresponders were estimated to be 4.3, 4.7, 
and 26.1%, respectively. They suggested that patients in the high-risk group of HCC after 
IFN therapy were those who showed no response, those who were older, or males. 
Sustained responders to IFN therapy usually show normal ALT levels continuously. In 
relapsers, ALT values usually become normal when HCV RNA becomes seronegative 
during therapy. Thus, the reduction in the necroinflammatory activity in the liver appears 
to be an important factor to prevent the development of HCC even when the eradication 
of HCV is not achieved. 
Another report indicated that the group at high risk for developing HCC in sustained 
responders to IFN therapy were older, more often male, and had more advanced 
histological disease stages [13]. In addition, Kasahara et al. showed that the risk of death 
from liver-related diseases in sustained and nonsustained virological responders was 
significantly lower compared with that in untreated patients [14]. Furthermore, sustained 
and transient biochemical responders were shown to have a reduced risk of liver-related 
death compared to biochemical nonresponders. Thus, it is likely that IFN treatment 
prevents liver-related death and improves survival of CH-C patients with virological as 
well as biochemical response. 
In the present case, the patient had mild fatty liver and diabetes mellitus without need 
for medication. The liver biopsy specimen at the time of operation (before operation) 
revealed liver damage of F2/A1. This finding was almost the same compared with that at 
the start of IFN therapy 12 years earlier. We considered the possibility that the presence of 
nonalcoholic fatty liver disease (NAFLD) might contribute, at least in part, to the 
development of HCC. NAFLD is a clinicopathological term that encompasses a disease 
spectrum ranging from simple triglyceride accumulation in hepatocyte (hepatic steatosis) 
to hepatic steatosis with inflammation (steatohepatitis), fibrosis, and cirrhosis [15]. 
Judging from the clinicopathological features in the current case, we could not exclude 
the influence of NAFLD for the development of HCC, while the pathological role of 
NAFLD might be limited. 
Although it has been reported that HCC rarely develops long after eradication of HCV 
[9–11], all patients with chronic HCV infection should be followed as long as possible for  
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the potential development of HCC, even sustained virological responders to IFN therapy. 
More careful follow-up is recommended, particularly when patients have complications 
such as NAFLD. 
 
 
 
Table 1. Laboratory data on admission 
Peripheral blood   
WBC 6,900/μl 
RBC 436  ×  10
4/μl 
Hb 14.4  g/dl 
Ht 40.2% 
Plt  25.3 × 10
4/μl 
Coagulation  
PT 102% 
HPT 116% 
Tumor marker   
AFP 4.0  ng/ml 
AFP-L3 0% 
PIVKA-2 18  AU/ml 
Blood chemistry   
AST 22  IU/l 
ALT 23  IU/l 
LDH 246  IU/l 
T-Bil 0.88  mg/dl 
ALP 246  IU/l 
γ-GTP 29  IU/l 
T.P 7.4  g/dl 
Alb 4.5  g/dl 
T-Cho 159  mg/dl 
BS 128  mg/dl 
HbA1c 6.8% 
Viral marker   
HBsAg negative 
HCVAb positive 
HCV-RNA negative 
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Fig. 1. On dynamic CT, the nodule on liver S8 area revealed a tumor staining of 4.0 cm in diameter in 
the early arterial phase (a) and modest washout density in the post-vascular phase (b). 
 
 
 
Fig. 2. Celiac angiography revealed a hypervascular tumor with proliferation of fine tumor vessels 
(which also showed nodular and mosaic features) at the S4/8 region of the liver, just below the dome of 
right diaphragm. 
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Fig. 3. Percutaneous liver biopsy was performed at the noncancerous lesion, and the specimen showed 
mild inflammation of grade A1 (a, HE stain; original magnification ×200) and fibrosis of stage F2 
(b, Azan stain; original magnification ×100), accompanied by mild steatosis. 
 
 
 
Fig. 4. Histological study of the resected specimen revealed that the tumor was a moderately 
differentiated HCC. 
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